13 unchanged sentences
Use of Proceeds
−Removed: On December 3, 2020, Silverback Therapeutics, Inc.
−Removed: (“Silverback”) commenced its initial public offering (“IPO”) pursuant to a registration statement on Form S-1 (File No.
−Removed: 333-250009) that was declared effective by the SEC on December 3, 2020, for 11,500,000 shares of its common stock for sale to the public at a price of $21.00 per share.
−Removed: In addition, in December 2020, the underwriters exercised their over-allotment option to purchase 1,725,000 additional shares of Silverback common stock in the initial public offering at the public offering price of $21.00 per share, such that the aggregate offering price of the IPO was $277.7 million.
−Removed: The net offering proceeds to Silverback, after deducting underwriting discounts and commissions and offering costs, were $255.3 million.
−Removed: No offering expenses were paid directly or indirectly to any of the Silverback directors or officers (or their associates) or persons owning 10% or more of any class of Silverback’s equity securities or to any other affiliates.
−Removed: The underwriters for the Silverback initial public offering were Goldman Sachs & Co.
−Removed: LLC, SVB Leerink LLC, Stifel, Nicolaus & Company, Incorporated, and H.C.
−Removed: Wainwright & Co., LLC.
−Removed: On November 8, 2022, Silverback completed its reverse merger with privately-held ARS Pharmaceuticals, Inc.
−Removed: On November 9, 2022, the combined company changed its name to ARS Pharmaceuticals, Inc.
−Removed: The net proceeds from the IPO are held in cash and cash equivalents, primarily in treasury money market accounts, and investments, primarily in U.S.
−Removed: Treasury securities.
−Removed: Through December 31, 2024, approximately $243.0 million of the net proceeds from the IPO have been used, of which, (i) an estimated $51.7 million was used toward development of Silverback’s product candidates, (ii) $0.8 million was used to repay outstanding indebtedness, (iii) $16.0 million was used for transaction costs related to the Merger, including $7.0 million in severance and change in control benefit payments made to Silverback’s former officers, (iv) an estimated $65.4 million was used for development and pre-commercial launch activities related to neffy , (v) an estimated $78.1 million was used for working capital and general corporate purposes, and (vi) an estimated $31.0 million was used for commercial-related activities.
−Removed: There have been no updates to the planned use of proceeds information from the IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on December 4, 2020, except as otherwise disclosed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2022, and our Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2022.
−Removed: We intend to use the remaining net proceeds from the IPO, together with our existing cash and cash equivalents, to fund the manufacture and commercialization of neffy for the emergency treatment of Type I allergic reactions and other indications, if approved, as well as for working capital and other general corporate purposes.
−Removed: We may also use a portion of the net proceeds from the IPO to license, acquire or invest in complementary businesses, technologies, products or assets.
−Removed: However, we have no current commitments or obligations to do so.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.